In another study, where patients with melanoma treated with Ipilimumab (CTLA-4 inhibitor) were evaluated, the patients who did not respond to the treatment reveal high rates of mutations in the IFN-γ pathway genes, like JAK2, interferon-gamma receptor 1 and 2 (IFNGR1/2) and interferon regulatory factor 1 (IRF1) [86,97]. This evidence concerns the gene IRF1 and melanoma.